With Underwater HD Video, the TG-320 offers the reliability of the ideal vacation camera.
ENGADGET: Olympus unveils a cavalcade of point and shoot cameras and a PEN lens at CES
Additionally, a combination clinical study of TG-1101 with Revlimid will be started in the fourth quarter of 2012.
FORBES: Don't Be Surprised If Underpriced Small-Cap Biotechs Catch Investors' Eye Once Again
In addition to being perfect for the ocean and mountains, the TG-625 is lightweight and compact, making it perfect for taking anywhere.
ENGADGET: Olympus Stylus TG-625 Tough adds AF light for tricky shots in rough situations
The STYLUS TG-625 is also equipped with Multi-Motion Movie IS image stabilization.
ENGADGET: Olympus Stylus TG-625 Tough adds AF light for tricky shots in rough situations
Express your inner artist with the Olympus TG-320's in-camera Magic Art Filters that enable users to enhance and customize images as they're being captured.
ENGADGET: Olympus unveils a cavalcade of point and shoot cameras and a PEN lens at CES
The rugged Olympus TG-320 is designed to take the hard knocks of everyday life, so you know that the memories it captures will be protected.
ENGADGET: Olympus unveils a cavalcade of point and shoot cameras and a PEN lens at CES
The analysis only uses U.S. revenue estimates generated from TG-1101 in relapsed and refractory NHL and CLL patient populations, as well as its current cash flow position.
FORBES: Don't Be Surprised If Underpriced Small-Cap Biotechs Catch Investors' Eye Once Again
The currently ongoing TG-1101 Phase 1 trial in NHL patients will have data in mid-2013, and begin to enroll Phase 2 part patients, as well, with more data expected at the ASH conference in 2013, says the analyst.
FORBES: Don't Be Surprised If Underpriced Small-Cap Biotechs Catch Investors' Eye Once Again
The day before the opening today of the ASH conference in Atlanta, TG Therapeitics announced it has initiated a phase 1 and 2 clinical trials to evaluate the safety, tolerability and efficacy of its product, TG-1101, a novel third-generation anti-CD20 monoclonal antibody, in combination with Revilimid for patients with relapsed or refractory B-cell lymphoid malignancies who were previously treated with anti-CD20 antibody therapy.
FORBES: Don't Be Surprised If Underpriced Small-Cap Biotechs Catch Investors' Eye Once Again
应用推荐